JP6388606B2 - 生物学的サンプルの質を評価するための手段及び方法 - Google Patents
生物学的サンプルの質を評価するための手段及び方法 Download PDFInfo
- Publication number
- JP6388606B2 JP6388606B2 JP2015557553A JP2015557553A JP6388606B2 JP 6388606 B2 JP6388606 B2 JP 6388606B2 JP 2015557553 A JP2015557553 A JP 2015557553A JP 2015557553 A JP2015557553 A JP 2015557553A JP 6388606 B2 JP6388606 B2 JP 6388606B2
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- sample
- evaluated
- quality
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 117
- 239000012472 biological sample Substances 0.000 title claims description 55
- 239000000090 biomarker Substances 0.000 claims description 217
- 239000000523 sample Substances 0.000 claims description 123
- 238000012545 processing Methods 0.000 claims description 81
- 210000002381 plasma Anatomy 0.000 claims description 73
- 210000004369 blood Anatomy 0.000 claims description 61
- 239000008280 blood Substances 0.000 claims description 61
- 238000004458 analytical method Methods 0.000 claims description 48
- 206010018910 Haemolysis Diseases 0.000 claims description 43
- 230000008588 hemolysis Effects 0.000 claims description 43
- 238000011109 contamination Methods 0.000 claims description 35
- 210000000601 blood cell Anatomy 0.000 claims description 32
- 230000002035 prolonged effect Effects 0.000 claims description 31
- 238000007710 freezing Methods 0.000 claims description 23
- 230000008014 freezing Effects 0.000 claims description 23
- 230000023555 blood coagulation Effects 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 11
- 238000011156 evaluation Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000004422 calculation algorithm Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 238000001303 quality assessment method Methods 0.000 claims description 5
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 4
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 239000002207 metabolite Substances 0.000 description 38
- 238000004949 mass spectrometry Methods 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 28
- 238000004817 gas chromatography Methods 0.000 description 15
- 238000013480 data collection Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000004811 liquid chromatography Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 238000013500 data storage Methods 0.000 description 11
- 238000002705 metabolomic analysis Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000012620 biological material Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000005526 G1 to G0 transition Effects 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000004590 computer program Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001212 derivatisation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000001431 metabolomic effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000007884 metabolite profiling Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000004885 tandem mass spectrometry Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 4
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 150000002066 eicosanoids Chemical class 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000000009 pyrolysis mass spectrometry Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009932 biopreservation Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- 238000006198 methoxylation reaction Methods 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012764 semi-quantitative analysis Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000006227 trimethylsilylation reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Chemical class 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000009120 phenotypic response Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- -1 small molecule compound Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764640P | 2013-02-14 | 2013-02-14 | |
| US201361764625P | 2013-02-14 | 2013-02-14 | |
| EP13155310 | 2013-02-14 | ||
| US61/764,640 | 2013-02-14 | ||
| EP13155318.2 | 2013-02-14 | ||
| EP13155318 | 2013-02-14 | ||
| US61/764,625 | 2013-02-14 | ||
| EP13155310.9 | 2013-02-14 | ||
| PCT/IB2014/059002 WO2014125443A1 (en) | 2013-02-14 | 2014-02-14 | Means and methods for assessing the quality of a biological sample |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018152554A Division JP2019039915A (ja) | 2013-02-14 | 2018-08-14 | 生物学的サンプルの質を評価するための手段及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510414A JP2016510414A (ja) | 2016-04-07 |
| JP2016510414A5 JP2016510414A5 (enExample) | 2017-03-16 |
| JP6388606B2 true JP6388606B2 (ja) | 2018-09-12 |
Family
ID=51353544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557553A Expired - Fee Related JP6388606B2 (ja) | 2013-02-14 | 2014-02-14 | 生物学的サンプルの質を評価するための手段及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160003799A1 (enExample) |
| EP (1) | EP2956127A4 (enExample) |
| JP (1) | JP6388606B2 (enExample) |
| KR (1) | KR20150119118A (enExample) |
| CN (1) | CN105120852A (enExample) |
| AU (1) | AU2014217452B2 (enExample) |
| BR (1) | BR112015019453A2 (enExample) |
| CA (1) | CA2900031A1 (enExample) |
| DE (1) | DE112014000822T5 (enExample) |
| IL (1) | IL240346A0 (enExample) |
| WO (1) | WO2014125443A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160146727A (ko) * | 2014-03-26 | 2016-12-21 | 메타노믹스 헬스 게엠베하 | 대사물 패널에 기초하여 혈액 샘플의 품질을 결정하기 위한 수단 및 방법 |
| CN104713970B (zh) * | 2015-04-01 | 2017-03-15 | 山东省肿瘤医院 | 一种血清代谢组学分析模型的构建方法 |
| US10890592B2 (en) | 2015-11-04 | 2021-01-12 | Metabolon, Inc. | Automated sample quality assessment |
| CN105996126B (zh) * | 2016-07-12 | 2019-06-14 | 福建中烟工业有限责任公司 | 天冬氨酸甘油酯用于降低卷烟烟气中苯酚释放量的用途 |
| JP6779500B2 (ja) | 2017-03-30 | 2020-11-04 | 株式会社島津製作所 | クロマトグラフ質量分析方法及び装置 |
| EP3628068A4 (en) * | 2017-05-02 | 2020-12-30 | Liquid Biosciences, Inc. | SYSTEMS AND METHODS FOR DETERMINING THE ATTRIBUTES OF BIOLOGICAL SAMPLES |
| AU2019371238A1 (en) * | 2018-10-30 | 2021-06-03 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
| JP7348626B2 (ja) * | 2019-07-17 | 2023-09-21 | 国立大学法人山梨大学 | 生体試料の状態評価装置、システム、方法、およびプログラム |
| CN111402961B (zh) * | 2020-02-28 | 2020-11-17 | 上海鹿明生物科技有限公司 | 一种多物种gc-ms内源性代谢物数据库及其建立方法 |
| CN113433239A (zh) * | 2021-06-25 | 2021-09-24 | 郑州大学第一附属医院 | 一种用于贲门癌诊断的标志物及试剂盒 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232396A1 (en) * | 2002-02-22 | 2003-12-18 | Biolife Solutions, Inc. | Method and use of protein microarray technology and proteomic analysis to determine efficacy of human and xenographic cell, tissue and organ transplant |
| WO2007064294A1 (en) * | 2005-11-29 | 2007-06-07 | Denator Aktiebolag | Method for determining the quality of a biological sample |
| US8026049B2 (en) * | 2007-03-23 | 2011-09-27 | Wisconsin Alumni Research Foundation | Noninvasive measurement and identification of biomarkers in disease state |
| EP2164977B1 (en) * | 2007-07-17 | 2013-10-30 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods using the same |
| US8927219B2 (en) * | 2007-11-22 | 2015-01-06 | Japan Advanced Institute Of Science And Technology | Method for evaluation of quality of blood sample |
| CN104127438B (zh) * | 2008-02-22 | 2021-01-08 | 新加坡科技研究局 | 间充质干细胞颗粒 |
| US8026102B2 (en) * | 2009-01-21 | 2011-09-27 | Blaze Medical Devices, LLC | Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification |
| US20120197539A1 (en) * | 2009-10-09 | 2012-08-02 | Carolyn Slupsky | Methods for diagnosis, treatment and monitoring of patient health using metabolomics |
| US20140087401A1 (en) * | 2011-06-07 | 2014-03-27 | Alexander Oliver Vortmeyer | Biomarkers for Assessment of the Molecular Quality in Biospecimens |
-
2014
- 2014-02-14 BR BR112015019453A patent/BR112015019453A2/pt not_active Application Discontinuation
- 2014-02-14 AU AU2014217452A patent/AU2014217452B2/en not_active Expired - Fee Related
- 2014-02-14 DE DE112014000822.2T patent/DE112014000822T5/de not_active Withdrawn
- 2014-02-14 CN CN201480020954.7A patent/CN105120852A/zh active Pending
- 2014-02-14 CA CA2900031A patent/CA2900031A1/en not_active Abandoned
- 2014-02-14 JP JP2015557553A patent/JP6388606B2/ja not_active Expired - Fee Related
- 2014-02-14 KR KR1020157024681A patent/KR20150119118A/ko not_active Withdrawn
- 2014-02-14 EP EP14751739.5A patent/EP2956127A4/en not_active Withdrawn
- 2014-02-14 US US14/767,059 patent/US20160003799A1/en not_active Abandoned
- 2014-02-14 WO PCT/IB2014/059002 patent/WO2014125443A1/en not_active Ceased
-
2015
- 2015-08-04 IL IL240346A patent/IL240346A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014217452A1 (en) | 2015-08-20 |
| CN105120852A (zh) | 2015-12-02 |
| JP2016510414A (ja) | 2016-04-07 |
| EP2956127A4 (en) | 2016-10-05 |
| DE112014000822T5 (de) | 2015-10-29 |
| AU2014217452B2 (en) | 2018-10-25 |
| WO2014125443A1 (en) | 2014-08-21 |
| EP2956127A1 (en) | 2015-12-23 |
| IL240346A0 (en) | 2015-09-24 |
| US20160003799A1 (en) | 2016-01-07 |
| KR20150119118A (ko) | 2015-10-23 |
| BR112015019453A2 (pt) | 2017-07-18 |
| CA2900031A1 (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6388606B2 (ja) | 生物学的サンプルの質を評価するための手段及び方法 | |
| JP6141387B2 (ja) | 肝疾患を診断する方法 | |
| Lin et al. | High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis | |
| JP6286475B2 (ja) | 対象において膵臓がんを診断する手段及び方法 | |
| JP2017512996A (ja) | 代謝産物パネルに基づく血液サンプルの品質の決定のための手段および方法 | |
| CN101443663A (zh) | 诊断糖尿病的工具和方法 | |
| Hamza et al. | Proteomics of prostate cancer serum and plasma using low and high throughput approaches | |
| Plubell et al. | Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer | |
| JP6389184B2 (ja) | サンプルにおいて代謝産物疾患バイオマーカーのクリアランス正規化量を決定するための手段及び方法 | |
| JP2014517300A (ja) | 多発性硬化症を診断する方法 | |
| Kiseleva et al. | Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring | |
| JP2019039915A (ja) | 生物学的サンプルの質を評価するための手段及び方法 | |
| JP2017523418A (ja) | 生物学的サンプルの品質を評価するための手段及び方法 | |
| Di Tommaso et al. | Quantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis | |
| Di Tommaso et al. | Quantification of amyloid protein enrichment by mass spectrometry improves amyloidosis typing | |
| CN119916028A (zh) | 一种渐冻症相关的标志物及其试剂盒 | |
| CN120468332A (zh) | 一组代谢标志物在制备双相情感障碍诊断试剂盒方面的应用 | |
| CN115219727A (zh) | 与库欣综合征诊断相关的代谢物 | |
| JP2020034556A (ja) | 前立腺癌の判定方法 | |
| JP2018163071A (ja) | 関節リウマチに関するペプチドマーカー |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20160218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170209 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170209 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180201 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180717 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180814 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6388606 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |